Shizuoka Cardiovascular events Prospective Study - SCOPE

Ko Ryo0 个研究点目标入组 200 人开始时间: 2021年11月19日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with solid tumor who have received no prior chemotherapy or no more than two regimens of chemotherapy.
•2) Anticancer therapy with regimens including immune checkpoint inhibitors or angiogenesis inhibitors (both antibody and tyrosine kinase inhibitors are acceptable) will be started within 28 days of enrollment.
•3) At least 20 years old at the time of registration.
•4) The treating investigator has determined that anticancer treatment is possible.
•5) Survival of at least 24 weeks after enrollment is expected.
•6) The patient's written consent to participate in the research has been obtained.

•1) Patients who are scheduled to receive only local or endocrine therapy as anticancer therapy.
•2) Patients scheduled to receive chemoradiation therapy in which the chest area will be irradiated.
•3) Patients with a history of treatment with immune checkpoint inhibitors or angiogenesis inhibitors.
•4) Patients with acute coronary syndromes (myocardial infarction, angina pectoris), acute heart failure, or other urgent cardiac conditions that require treatment or procedures at the time of enrollment.
•5) Patients with obvious cognitive decline or concomitant psychiatric disorders who are judged to be unable to participate in the study.
•6) Patients who are judged by the treating investigators to be inappropriate to participate in this study for anti-cancer treatment.

发起方

Ko Ryo